Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients
INTRODUCTION: Cardiovascular diseases (CVDs) are among the most frequently identified comorbidities in hospitalized patients with COVID-19. Patients with CV comorbidities are typically prescribed with long-term medications. We reviewed the management of co-medications prescribed for CVDs among hospitalized COVID-19 patients.
AREAS COVERED: There is no specific contraindication or caution related to COVID-19 on the use of antihypertensives unless patients develop severe hypotension from septic shock where all antihypertensives should be discontinued or severe hyperkalemia in which continuation of renin-angiotensin system inhibitors is not desired. The continuation of antiplatelet or statin is not desired when severe thrombocytopenia or severe transminitis develop, respectively. Patients with atrial fibrillation receiving oral anticoagulants, particularly those who are critically ill, should be considered for substitution to parenteral anticoagulants.
EXPERT OPINION: An individualized approach to medication management among hospitalized COVID-19 patients with concurrent CVDs would seem prudent with attention paid to changes in clinical conditions and medications intended for COVID-19. The decision to modify prescribed long-term CV medications should be entailed by close follow-up to check if a revision on the decision is needed, with resumption of any long-term CV medication before discharge if it is discontinued during hospitalization for COVID-19, to ensure continuity of care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Expert review of cardiovascular therapy - 18(2020), 8 vom: 23. Aug., Seite 475-485 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 09.10.2020 Date Revised 17.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14779072.2020.1797492 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312766807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312766807 | ||
| 003 | DE-627 | ||
| 005 | 20231225145124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14779072.2020.1797492 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312766807 | ||
| 035 | |a (NLM)32700573 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2020 | ||
| 500 | |a Date Revised 17.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Cardiovascular diseases (CVDs) are among the most frequently identified comorbidities in hospitalized patients with COVID-19. Patients with CV comorbidities are typically prescribed with long-term medications. We reviewed the management of co-medications prescribed for CVDs among hospitalized COVID-19 patients | ||
| 520 | |a AREAS COVERED: There is no specific contraindication or caution related to COVID-19 on the use of antihypertensives unless patients develop severe hypotension from septic shock where all antihypertensives should be discontinued or severe hyperkalemia in which continuation of renin-angiotensin system inhibitors is not desired. The continuation of antiplatelet or statin is not desired when severe thrombocytopenia or severe transminitis develop, respectively. Patients with atrial fibrillation receiving oral anticoagulants, particularly those who are critically ill, should be considered for substitution to parenteral anticoagulants | ||
| 520 | |a EXPERT OPINION: An individualized approach to medication management among hospitalized COVID-19 patients with concurrent CVDs would seem prudent with attention paid to changes in clinical conditions and medications intended for COVID-19. The decision to modify prescribed long-term CV medications should be entailed by close follow-up to check if a revision on the decision is needed, with resumption of any long-term CV medication before discharge if it is discontinued during hospitalization for COVID-19, to ensure continuity of care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiovascular | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a drug-drug interaction | |
| 650 | 4 | |a renin-angiotensin system | |
| 650 | 4 | |a statin | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Thiruchelvam, Kaeshaelya |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of cardiovascular therapy |d 2003 |g 18(2020), 8 vom: 23. Aug., Seite 475-485 |w (DE-627)NLM147291070 |x 1744-8344 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2020 |g number:8 |g day:23 |g month:08 |g pages:475-485 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14779072.2020.1797492 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2020 |e 8 |b 23 |c 08 |h 475-485 | ||